Business News

With EUR 56m investment, Krka doubles R&D capacities

Novo Mesto, 01 October (STA) - Krka, the Novo Mesto-seated pharmaceuticals group, has launched a new research and development centre to nearly double its R&D, and control and analysis capacities.

"With the new facility, which has state-of-the-art equipment for laboratories, analysis and technology, we've almost doubled Krka's development as well as control and analysis capacities, thus significantly improving R&D, which is at the core of Krka's vertically integrated business model," said Aleš Rotar, R&D director.

The Research and Control Centre 4 (RKC 4) is a EUR 55.6 million investment located on the outskirts of Novo Mesto, and is connected with a bridge to RKC 3 and then on to RKC 1.

The eight-storey building with 18,000 square metres of offices accommodates new control and analysis labs and R&D areas, CEO Jože Colarič said before Tuesday's inauguration.

Rotar stressed the centre was especially important for pilot development of solid pharmaceuticals as a key component in the development of new products.

The company believes RKC 4 will enable it to carry out advanced R&D tests at the very early laboratory stage and define the key features of a product in early stages.

In the first half of 2019, the group posted a net profit of EUR 139.9 million, up 37% from the same period in 2018, on EUR 761.8 million sales revenue, up 12%.

The plan for this year is to finish with EUR 1.38 billion in sales revenue and EUR 172 million in net profit.

The group allocates 10% of its revenue for R&D and new technologies, and has more than 170 development projects for new products are under way.

It generates 29% of its sales with the new medicines which they have started selling over the past five years.

You might be also interested in:


We are here to help you.